Skip to content

The effect of kefir drink on non-alcoholic fatty liver disease

Effect of kefir drink on hepatic enzymes, lipid profiles, glycemic indices,inflammation, oxidative stress, anthropometric factors and blood pressure in patients with non-alcoholic fatty liver disease.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20170916036204N6
Enrollment
80
Registered
2018-08-03
Start date
2018-06-21
Completion date
Unknown
Last updated
2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease. non-alcoholic, fatty liver disease

Interventions

Intervention 1: Intervention group:received diet therapy + kefir drink 2 glasses(500 ml) every day for 8 weeks. Kefir will be purchased from Pegah Fars Factory. Intervention 2: Control group: received

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: grade 1,2 & 3 fatty liver, new fatty liver diagnosed patients, and fatty liver confirmed by physician. Alt>30 in males and ALt>19 in females. age: 18-65 BMI>25 controlled Diabetes and lipid profile.

Exclusion criteria

Exclusion criteria: presence of another type of liver disease, cirrhosis, hepatitis B and C, cardiovascular and kidney disease, autoimmune, hypothyroidism, wilson, cystic fibrosis, Deficiency of alpha-1-antitrypsin 1, inflammatory bowel disease and hemochromatosis. using alcohol taking nutritional and probiotic supplements within the previous 6 weeks. having weight loss more than 3 Kg within 3 month ago participating in other trials in the last 6 month being pregnant or breast feeding do not want to participate in this trial.

Design outcomes

Primary

MeasureTime frame
Alanine aminotransferase. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: ALT kit.;Aspartate transaminase. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: AST kit.;Weight. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: seca scale.

Secondary

MeasureTime frame
Blood pressure. Timepoint: before intervention and 8 weeks after intervention. Method of measurement: Mercury barometric device.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNadia Razmjooei

Shiraz University of Medical Sciences

nadiarazmjoee@yahoo.com+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026